(Q43162626)

English

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance

scientific article published in March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 November 2017

Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance (English)

1 reference

Europe PubMed Central

15 November 2017

author name string

Pushpalatha K A Idirisinghe

1

1 reference

Europe PubMed Central

15 November 2017

Aye Aye Thike

2

1 reference

Europe PubMed Central

15 November 2017

Poh Yian Cheok

3

1 reference

Europe PubMed Central

15 November 2017

Gary Man-Kit Tse

4

1 reference

Europe PubMed Central

15 November 2017

Philip Chi-Wai Lui

5

1 reference

Europe PubMed Central

15 November 2017

Stephanie Fook-Chong

6

1 reference

Europe PubMed Central

15 November 2017

Nan Soon Wong

7

1 reference

Europe PubMed Central

15 November 2017

Puay Hoon Tan

8

1 reference

Europe PubMed Central

15 November 2017

language of work or name

1 reference

American Journal of Clinical Pathology

publication date

1 March 2010

1 reference

Europe PubMed Central

15 November 2017

American Journal of Clinical Pathology

1 reference

Europe PubMed Central

15 November 2017

133

1 reference

Europe PubMed Central

15 November 2017

3

1 reference

Europe PubMed Central

15 November 2017

416-429

1 reference

Europe PubMed Central

15 November 2017

Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Growth factor receptors in breast cancer: potential for therapeutic intervention.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Problems and solutions in the evaluation of hormone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Inter-site variation of oestrogen receptors in human breast cancers

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

The variability of estrogen receptors in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Impact of metastatic estrogen receptor and progesterone receptor status on survival

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Variation in receptor status between primary and metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

HER2 gene status in primary breast cancers and matched distant metastases

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1309%2FAJCPJ57FLLJRXKPV

21 January 2018

Identifiers

10.1309/AJCPJ57FLLJRXKPV

1 reference

Europe PubMed Central

15 November 2017

1 reference

Europe PubMed Central

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43162626&oldid=1982378064"